Articles tagged "Immunosuppression"

2015 American Transplant Congress
Toxicity Driven Conversion to Belatacept in Kidney Transplant Recipients
E. Cohen, W. Asch, R. Formica, E. Tichy.
Yale-New Haven Transplantation Center, New Haven, CT.
Purpose: Evaluate the result of conversion to belatacept from calcineurin inhibitor (CNI) or TOR inhibitor based regimens due to toxicities in kidney transplant recipients (KTR).Methods:…
2015 American Transplant Congress
Phenotypic Personalized Medicine: Mechanism-Independent Convergence Into Target Serum Tacrolimus Levels for Optimized Liver Transplant Immunosuppression
A. Zarrinpar,¹ A. Silva,² D.-K. Lee,³ N. Datta,¹ C.-M. Ho,² D. Ho.³
¹Surgery-Division of Liver and Pancreas Transplantation, UCLA, Los Angeles, CA; ²Mechanical Engineering, UCLA, Los Angeles, CA; ³Bioengineering, and Oral Biology and Medicine, UCLA, Los Angeles, CA.
PURPOSE:Immunosuppressive drugs such as tacrolimus have narrow therapeutic ranges and their dosing variability necessitates intensive drug monitoring. This study aimed to use Feedback System Control…
2015 American Transplant Congress
NK Cells of Kidney Transplant Recipients Show a Reduced Capacity to Produce Cytokines But Retain Their Cytotoxic Capacity
U. Hoffmann,¹ C. Neudoerfl,¹ K. Daemen,¹ J. Keil,¹ C. Blume,^2,3 F. Lehner,⁴ H. Haller,² C. Falk.^1,5
¹Inst. of Transplant Immunology, IFB-Tx, Hanover Medical School, Hanover, Germany; ²Dept. of Nephrology and Hypertension, Hanover Medical School, Hanover, Germany; ³Inst. of Technical Chemistry, Leibniz University Hanover, Hanover, Germany; ⁴Dept. of General, Visceral, and Transplantation Surgery, Hanover Medical School, Hanover, Germany; ⁵German Center for Infection Research, Braunschweig, Germany.
The role of NK cells in either graft rejection or tolerance induction is still discussed controversially. In order to clarify the effect of long-term immunosuppression…
2015 American Transplant Congress
Reduced Intensity Immunosuppression Protocol Lowers Drug Costs and May Decrease Incidences of BK Viremia and Readmissions After Kidney and Kidney/Pancreas Transplant
M. Mariski,¹ A. DeGolovine,² W. Dar,² J. Bynon,² H. Adrogué,² M. Hobeika.²
¹Dept of Pharmacy, Memorial Hermann Texas Medical Center, Houston, TX; ²Division of Immunology and Organ Transplantation, University of Texas, Houston, TX.
Purpose: To evaluate the effects of a reduced intensity immunosuppression protocol on drug costs and rates of BK viremia and readmissions.Methods: In response to high…
2015 American Transplant Congress
Long-Term Results After Heart Transplantation – A Randomized Trial Comparing Tacrolimus Versus Cyclosporine A in Combination With Mycophenolate Mofetil After a Mean Duration of 15 Years
S. Guethoff,¹ C. Grinninger,¹ B. Reichart,² P. Ueberfuhr,¹ C. Hagl,¹ B. Meiser.²
¹Department of Cardiac Surgery, Ludwig-Maximilians University, Munich, Germany; ²Transplantation Center, Ludwig-Maximilians University, Munich, Germany.
Purpose. Development of cardiac allograft vasculopathy (CAV), renal dysfunction and malignancies are the main risks due to long-term immunosuppressive therapy after heart transplantation (HTx). We…
2015 American Transplant Congress
Favorable Results of ABO Incompatible Renal Transplantation Without B Cell Targeted Therapy: Advantages and Disadvantages of Rituximab Pretreatment
M. Okada,¹ K. Futamura,¹ K. Itou,¹ T. Yamamoto,¹ T. Hiramitsu,¹ M. Tsujita,¹ N. Goto,¹ S. Narumi,¹ Y. Watarai,¹ A. Katayama,² K. Uchida,³ T. Kobayashi.⁴
¹Nagoya Daini Red Cross Hospital, Nagoya, Japan; ²Masuko Memorial Hospital, Nagoya, Japan; ³Aichi Medical University, Nagakute, Japan; ⁴Nagoya University School of Medicine, Nagoya, Japan.
INTRODUCTIONThe outcome of ABO-incompatible transplantation (ABO-I) has been reported to be comparable to that of ABO-identical/compatible transplantation (ABO-Id/C), which is considered to be due to…
2015 American Transplant Congress
Final Results from the BENEFIT-EXT Trial: A 7 Year Follow-Up of Belatacept Treated Patients
S. Florman,¹ J. Medina Pestana,² M. Rial,³ L. Rostaing,⁴ D. Kuypers,⁵ F. Mühlbacher,⁶ M. Polinsky,⁷ U. Meier-Kriesche,⁷ J. Grinyó,⁸ A. Durrbach.⁹
¹Mt Sinai Med Ctr, NY; ²Hosp do Rim e Hipertensão, Sao Paulo, Brazil; ³Inst de Nefrologia, Buenos Aires, Argentina; ⁴Univ Hospital, Toulouse, France; ⁵Univ Hospital Leuven, Leuven, Belgium; ⁶Vienna Transplantation Ctr, Vienna, Austria; ⁷BMS, Lawrenceville; ⁸Univ Hosp Bellvitge, Barcelona, Spain; ⁹Univ Hosp of Bicêtre, Villejuif, France.
Background: At 3 and 5yrs post-transplant, BENEFIT-EXT showed a renal function benefit and consistent safety in belatacept (bela) treated pts vs cyclosporine (CsA). Final 7…
2015 American Transplant Congress
Effect of Intrapatient Variability and Mean Tacrolimus Levels in Renal Transplant Patients
D. Goodall, M. Willicombe, A. McLean, D. Taube.
Imperial College Renal and Transplant Centre, Hammersmith Hospital, London, United Kingdom.
IntroductionNonadherence (NA) to immunosuppressive medication and adherence to immunosuppressive protocols is a potent risk factor for rejection and graft loss, which can be both patient…
2015 American Transplant Congress
Efficacy and Safety of Once-Daily Everolimus With Minimized Once-Daily Tacrolimus After Liver Transplantation
P. De Simone,¹ P. Carrai,¹ L. Coletti,¹ A. Precisi,² D. Campani,³ F. Filipponi.¹
¹Hepatobiliary Surgery and Liver Transplantation, University of Pisa Medical School Hospital, Pisa, Italy; ²Laboratory, University of Pisa Medical School Hospital, Pisa, Italy; ³Pathology, University of Pisa Medical School Hospital, Pisa, Italy.
Background: The everolimus (EVR) pharmacokinetic profile allows for its once daily (OD) administration. We tested the efficacy and safety of a combination schedule of OD-EVR…
2015 American Transplant Congress
Emerging Application of Active Immune Targeted Delivery in Transplantation
M. Uehara,¹ A. Jamil,¹ M. McGrath,¹ Z. Solhjou,¹ N. Banouni,¹ S. Tullius,² C. Jianjun,³ R. Abdi.¹
¹Renal Division, Transplantation Research Center, Brigham and Women's Hospital, Harvard Medical Shcool, Boston, MA; ²Division of Transplant Surgery, Brigham and Women's Hospital, Boston, MA; ³Materials Science and Engineering, University of Illinois at Urbana-Champaign, Champaingn, IL.
Targeted nanodelivery has created enormous excitement as a transformative approach to deliver therapeutics to tissues of interest. In recent years, we have made significant progress…